Mark Boguski, a founding director of the brain atlas project at the Allen Institute for Brain Science in Seattle, has left his post. Further details were not available at press time.
Peter Brocklesby is the new president of Applied DNA Sciences, which uses structure design to tweak plant DNA into anti-counterfeiting tags for various industries.
Matthias Mann, currently director of the Center for Experimental Bioinformatics at the University of Southern Denmark, will be a new director at the Max Planck Institute for Biochemistry beginning next May.
Steve Martin, longtime director of ABI’s proteomics research initiative acquired with PerSeptive Biosystems in 1998, is leaving to join a startup organization. Peter Juhasz will fill Martin’s position.
Also leaving home: three members of Compugen will soon have their emeritus status. Compugen confirmed that Kinneret Savitsky, vice president of biology research and development; Dorit Bitter, VP for computational life sciences R&D; and Michal Preminger, VP for protein therapeutics, are all slated to leave the company in the coming months.
John Yates was awarded the Biemann medal at the American Society for Mass Spectrometry’s annual meeting in May. The award recognizes significant accomplishment in the mass spec field early in one’s career, and Yates won for advances he made while at the University of Virginia in the 1980s working in Don Hunt’s lab.
Nanogen’s new president and COO is David Ludvigson, who’s promoted to the post from being executive VP and CFO. Ludvigson replaces Bruce Huebner, who resigned.
There’s a rash of new CFOs in town:
William Sims, formerly at Clontech Laboratories and Becton Dickinson, replaces Perlegen CFO Matthew Fust.
BioTrove appoints Alan Barber from Omnisonics Medical Technologies as its new head finance officer.
And Peter Wilver is promoted to the post at Thermo Electron starting this October, taking over for Theo Melas-Kyriazi.
Russell Singleton joins Perlegen, where he’ll be engineering and informatics VP, after a stint as president of his own company. Singleton has worked at Molecular Dynamics and KLA-Tencor.
Former Avidex head of drug discovery Phil Huxley becomes senior director of the same department at Belgium’s Galapagos Genomics.